These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 15284838)
1. Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection. Richard E; Robert E; Cario-André M; Ged C; Géronimi F; Gerson SL; de Verneuil H; Moreau-Gaudry F Gene Ther; 2004 Nov; 11(22):1638-47. PubMed ID: 15284838 [TBL] [Abstract][Full Text] [Related]
2. A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines. Richard E; Géronimi F; Lalanne M; Ged C; Redonnet-Vernhet I; Lamrissi-Garcia I; Gerson SL; de Verneuil H; Moreau-Gaudry F J Gene Med; 2003 Sep; 5(9):737-47. PubMed ID: 12950064 [TBL] [Abstract][Full Text] [Related]
3. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647 [TBL] [Abstract][Full Text] [Related]
4. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508 [TBL] [Abstract][Full Text] [Related]
5. Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Richard E; Mendez M; Mazurier F; Morel C; Costet P; Xia P; Fontanellas A; Geronimi F; Cario-André M; Taine L; Ged C; Malik P; de Verneuil H; Moreau-Gaudry F Mol Ther; 2001 Oct; 4(4):331-8. PubMed ID: 11592836 [TBL] [Abstract][Full Text] [Related]
6. G156A MGMT-transduced human mesenchymal stem cells can be selectively enriched by O6-benzylguanine and BCNU. Lee K; Gerson SL; Maitra B; Koç ON J Hematother Stem Cell Res; 2001 Oct; 10(5):691-701. PubMed ID: 11672516 [TBL] [Abstract][Full Text] [Related]
7. Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients. Davis BM; Reese JS; Lingas K; Gerson SL J Hematother Stem Cell Res; 2003 Aug; 12(4):375-87. PubMed ID: 12965075 [TBL] [Abstract][Full Text] [Related]
8. In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning. Zielske SP; Reese JS; Lingas KT; Donze JR; Gerson SL J Clin Invest; 2003 Nov; 112(10):1561-70. PubMed ID: 14617757 [TBL] [Abstract][Full Text] [Related]
9. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication. Davis BM; Humeau L; Dropulic B Mol Ther; 2004 Feb; 9(2):160-72. PubMed ID: 14759800 [TBL] [Abstract][Full Text] [Related]
10. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Persons DA; Allay ER; Sawai N; Hargrove PW; Brent TP; Hanawa H; Nienhuis AW; Sorrentino BP Blood; 2003 Jul; 102(2):506-13. PubMed ID: 12663444 [TBL] [Abstract][Full Text] [Related]
11. Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro. Zielske SP; Gerson SL Mol Ther; 2002 Apr; 5(4):381-7. PubMed ID: 11945064 [TBL] [Abstract][Full Text] [Related]
12. In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene. Larochelle A; Choi U; Shou Y; Naumann N; Loktionova NA; Clevenger JR; Krouse A; Metzger M; Donahue RE; Kang E; Stewart C; Persons D; Malech HL; Dunbar CE; Sorrentino BP J Clin Invest; 2009 Jul; 119(7):1952-63. PubMed ID: 19509470 [TBL] [Abstract][Full Text] [Related]
13. Lentivirus-mediated expression of mutant MGMTP140K protects human CD34+ cells against the combined toxicity of O6-benzylguanine and 1,3-bis(2-chloroethyl)-nitrosourea or temozolomide. Chinnasamy D; Fairbairn LJ; Neuenfeldt J; Treisman JS; Hanson JP; Margison GP; Chinnasamy N Hum Gene Ther; 2004 Aug; 15(8):758-69. PubMed ID: 15319033 [TBL] [Abstract][Full Text] [Related]
14. Successful therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction and fluorescence-based selection of hematopoietic cells. Fontanellas A; Mendez M; Mazurier F; Cario-André M; Navarro S; Ged C; Taine L; Géronimi F; Richard E; Moreau-Gaudry F; Enriquez De Salamanca R; de Verneuil H Gene Ther; 2001 Apr; 8(8):618-26. PubMed ID: 11320408 [TBL] [Abstract][Full Text] [Related]
15. Characterization of the P140K, PVP(138-140)MLK, and G156A O6-methylguanine-DNA methyltransferase mutants: implications for drug resistance gene therapy. Davis BM; Roth JC; Liu L; Xu-Welliver M; Pegg AE; Gerson SL Hum Gene Ther; 1999 Nov; 10(17):2769-78. PubMed ID: 10584923 [TBL] [Abstract][Full Text] [Related]
16. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts. Koç ON; Reese JS; Davis BM; Liu L; Majczenko KJ; Gerson SL Hum Gene Ther; 1999 Apr; 10(6):1021-30. PubMed ID: 10223735 [TBL] [Abstract][Full Text] [Related]
17. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow. Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363 [TBL] [Abstract][Full Text] [Related]
18. Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression. Ball CR; Pilz IH; Schmidt M; Fessler S; Williams DA; von Kalle C; Glimm H Blood; 2007 Sep; 110(6):1779-87. PubMed ID: 17496202 [TBL] [Abstract][Full Text] [Related]
19. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients. Bowman JE; Reese JS; Lingas KT; Gerson SL Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427 [TBL] [Abstract][Full Text] [Related]
20. Lentiviral MGMT(P140K)-mediated in vivo selection employing a ubiquitous chromatin opening element (A2UCOE) linked to a cellular promoter. Phaltane R; Lachmann N; Brennig S; Ackermann M; Modlich U; Moritz T Biomaterials; 2014 Aug; 35(25):7204-13. PubMed ID: 24875758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]